Low‐dose pembrolizumab in the treatment of advanced non‐small cell lung cancer

A dose of 200 mg 3‐weekly of pembrolizumab was approved by the Food and Drug Administration (FDA) as treatment for advanced non‐small cell lung cancer (NSCLC) without oncogenic drivers. This is despite evidence showing no difference in efficacy with 2 mg/kg. Our study aimed to assess the efficacy of...

Descripción completa

Detalles Bibliográficos
Autores principales: Low, Jia Li, Huang, Yiqing, Sooi, Kenneth, Ang, Yvonne, Chan, Zhi Yao, Spencer, Katie, Jeyasekharan, Anand Devaprasath, Sundar, Raghav, Goh, Boon Cher, Soo, Ross, Yong, Wei Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Cancer Therapy and Prevention
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545741/
https://www.ncbi.nlm.nih.gov/pubmed/33634869
http://dx.doi.org/10.1002/ijc.33534

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545741/
https://www.ncbi.nlm.nih.gov/pubmed/33634869
http://dx.doi.org/10.1002/ijc.33534

Ejemplares similares